Plasma-lyte

Phase 3Small molecule

AAlgemeen Ziekenhuis Maria Middelares

Plasma-lyte is one of 37 small molecule programs targeting Sepsis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SepsisActive, not recruiting

Postpartum HemorrhageActive, not recruiting

SepsisPhase 3

Active, not recruiting

Postpartum HemorrhagePreclinical

Active, not recruiting

Competition

Competitive Landscape

308 competitors in Sepsis

#DrugCompanyPhaseTrials

Plasma-lyte

AAlgemeen Ziekenhuis Maria Middelares

Phase 3

1 2

Corlanor

Amgen

Preclinical

2 3

Primaxin

Zemplar

Zyvox

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

3 7

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

2 8

Levaquin

WWim Janssens

Preclinical

1 9

Jardiance

Boehringer Ingelheim

Preclinical

1 10

Micardis

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Breast Reconstruction

NCT06080178

Clinical

Trials by Indication[1]

Blood Pressure2 trials

Decision Support for Intraoperative Low Blood Pressure

Completed·VVanderbilt University Medical Center·N/A·NCT02726620·22,435 enrolled

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

Completed·WWright State University·Phase 3·NCT05355974·42 enrolled

Sepsis1 trial

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

Completed·—·Phase 3·NCT04102371·9,041 enrolled

Intensive Care1 trial

Balanced Solution Versus Saline in Intensive Care Study

Completed·HHospital do Coracao·Phase 3·NCT02875873·11,075 enrolled

Postpartum Hemorrhage1 trial

Balanced Crystalloids in Postpartum Hemorrhage

Unknown status·FFundación Santa Fe de Bogota··NCT03824743·40 enrolled

Glycocalyx1 trial

0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis

Unknown status·RRegional Hospital Holstebro·Phase 4·NCT02528448·40 enrolled

1 more indication

Breast Reconstruction1 trial

Goal-directed Fluid Therapy During Deep Inferior Epigastric Perforator (DIEP) Free Flap Breast Reconstruction

Recruiting·AAlgemeen Ziekenhuis Maria Middelares·Phase 4·NCT06080178·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Plasma-lyte. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plasma-lyte compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plasma-lyte. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Algemeen Ziekenhuis Maria Middelares company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlgemeen Ziekenhuis Maria Middelares

Plasma-lyte

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Blood Pressure2 trials

Sepsis1 trial

Intensive Care1 trial

Postpartum Hemorrhage1 trial

Glycocalyx1 trial

Breast Reconstruction1 trial

References

Drug Info

Quick Facts

Related News